Sherry v. Chioini

219 F. Supp. 3d 608, 2016 U.S. Dist. LEXIS 147240, 2016 WL 6215994
CourtDistrict Court, E.D. Michigan
DecidedOctober 25, 2016
DocketCase No. 15-14198
StatusPublished

This text of 219 F. Supp. 3d 608 (Sherry v. Chioini) is published on Counsel Stack Legal Research, covering District Court, E.D. Michigan primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Sherry v. Chioini, 219 F. Supp. 3d 608, 2016 U.S. Dist. LEXIS 147240, 2016 WL 6215994 (E.D. Mich. 2016).

Opinion

OPINION AND ORDER (1) GRANTING DEFENDANTS’ MOTION TO DISMISS (ECF # 15) WITH RESPECT TO COUNTS I, III, AND IV OF PLAINTIFF’S COMPLAINT AND (2) ORDERING SUPPLEMENTAL BRIEFING WITH RESPECT TO COUNT II

MATTHEW F. LEITMAN, UNITED STATES DISTRICT JUDGE

This is a shareholder derivative action under Michigan law. Plaintiff Donald E. Sherry (“Sherry”) is a shareholder of nominal Defendant Rockwell Medical, Inc. (“Rockwell”). Sherry alleges that Rockwell’s Board of Directors (the “Board”) and certain corporate officers improperly enriched themselves by granting and/or accepting (1) so-called “spring loaded” stock options and/or (2) a greater number of stock options than permitted under the company’s compensation plan.

Prior to filing this action, Sherry sent a letter to the Board identifying this alleged wrongdoing and demanding that Rockwell investigate it and take appropriate action (the “Demand Letter”). In response, Rockwell asked the Oakland County Circuit Court (the “OCCC”) to appoint attorney S. Thomas Wienner (“Wienner”) as a disinterested person to investigate Sherry’s allegations and to determine whether Rockwell should pursue claims based upon the allegations. After the OCCC appointed Wienner, he conducted an investigation and determined that it would not be in Rockwell’s best interest to pursue claims arising out of Sherry’s allegations.

The Defendants now move for dismissal of Sherry’s claims. They seek that relief under a Michigan statute that, under certain circumstances, requires a court to dismiss derivative claims that a court-appointed disinterested person has determined should not be pursued. (See ECF # 15.) For the reasons explained below, the Court DISMISSES the claims that were the subject of Wienner’s determination (Counts I, III, and IV of the Complaint),

In a separate claim that was neither raised in the Demand Letter nor investigated by Wienner (Count II of the Complaint), Sherry alleges that the Board issued a misleading proxy statement to Rockwell’s shareholders in 2014. The Defendants have moved to dismiss this claim [611]*611on the ground that, among other things, Sherry lacks standing to assert it. For the reasons explained below, the Court concludes that it cannot rule on the motion to dismiss Count II until it receives and reviews supplemental briefs with respect to that claim.

I

A

Rockwell is a publicly-traded medical device and biopharmaceutical company. (See Wienner Report at 4, ECF # 15-10 at 5, Pg. ID 435.) For most of its history, “the great majority of [Rockwell’s] revenues have been derived from the manufacture and sale of concentrate solutions used during hemodialysis.” (Id. at 6, ECF # 15-10 at 7, Pg. ID 437.)

Rockwell’s President and CEO is Defendant Robert Chioini (“Chioini”). (See id. at 4, ECF # 15-10 at 5, Pg. ID 435.) Chioini also serves as Chairman of the Board. (See id.) The Board includes three outside directors: Defendants Patrick Bagley (“Bag-ley”), Ronald Boyd (“Boyd”), and Kenneth Holt (“Holt”). (See id. at 4-5, ECF # 15-10 at 5-6, Pg. ID 435-36.) Bagley, Boyd, and Holt comprise the Board’s “Compensation Committee.” (See id.) The remaining Defendants in this action—Thomas Klema (“Klema”), Ajay Gupta (“Gupta”), and Raymond Pratt (“Pratt”)—are Rockwell corporate officers. (See Compl., ECF #1 at ¶¶ 16-19, Pg. ID 6.)

In 2007, Rockwell’s shareholders approved, and the Board adopted, a “Long Term Incentive Plan” (the “Plan”). (See Wienner Report at 7, ECF # 15-10 at 8, Pg. ID 438.) The Plan authorizes the Board’s Compensation Committee “to grant various equity awards [i.e., stock options] to themselves, any other non-employee directors, executive officers, other employees, and consultants of [Rockwell].” (Compl., ECF # 1 at ¶ 21, Pg. ID 7.) The Plan further provides that “the exercise price of stock options [granted under the Plan] be set at no less than Rockwell’s ‘Fair Market Value’ on the date of the grant.” (Id. at ¶36, Pg. ID 12.) The Plan defines “Fair Market Value” as “the closing price of [Rockwell’s] Common Stock on the [NASDAQ] Stock Exchange for the Grant Date.” (Id.)

On April 4, 2014, the Board filed a Schedule 14A Proxy Statement with the United States Securities and Exchange Commission in which the Board “solicited shareholder approval of amendments to the Plan” (the “2014 Proxy Statement”). (Id. at ¶ 5, Pg. ID 4.) In the 2014 Proxy Statement, the Board sought to increase the number of stock options that the Compensation Committee could grant in a single fiscal year. (See id.) Rockwell’s shareholders approved the amendment on May 22, 2014. (See id. at ¶68, Pg. ID 23.)

B

The fall of 2014 was an important and busy time for Rockwell. For years, “Rockwell [had been] attempting to transition from being a medical supplier of dialysis concentrate products to being a specialty pharmaceutical company with higher margins.” (Wienner Report at 5, ECF # 15-10 at 6, Pg. ID 436.) Rockwell’s “primary effort” in this transformation had been “the development of a drug called Triferic, which is used to replace iron and maintain hemoglobin during hemodialysis treatments.” (Id.) In the fall of 2014, the Food and Drug Administration (the “FDA”) was nearing a decision on whether to approve Triferic, and it had scheduled a public session to review the drug on November 6, 2014. (See id. at 6-7, ECF # 15-10 at 7-8, Pg. ID 437-38).

In this same time frame, Rockwell was also negotiating a transaction with Baxter [612]*612Healthcare Corporation (“Baxter”). (See Compl. at ¶4, Pg. ID 3.) The proposed transaction called for Baxter to “serve as the exclusive distributor of Rockwell’s he-modialysis concentrate and ancillary products in the United States and selected foreign countries.” (Id.) Chioini, “in his capacity as [President of [Rockwell]” was the person negotiating with Baxter on Rockwell’s behalf. (Wienner Dep. at 116, ECF # 32-1 at 31, Pg. ID 826.)

On October 1, 2014, the Board met to address the Baxter transaction. (See id.) The Board voted to “authorize[ ]” the Baxter transaction and to give Chioini the “authority” to complete his negotiations and close on the transaction. (Id.)

At the conclusion of the full Board meeting, the Compensation Committee met. (See Wienner Report at 9, ECF # 15-10 at 10, Pg. ID 440.) During that meeting, the Compensation Committee granted an aggregate of 825,000 stock options (the “Option Awards”) as follows: 500,000 options to Chioini, 120,000 options to Klema, 50,-000 options each to Gupta and Pratt, and 35,000 options to each member of the committee. (See id. at 9-10, ECF # 15-10 at 10-11, Pg. ID 440-41.) The “exercise price of the [Option Awards] was $8.88 per share, which, consistent with [the Plan], was the closing price on the NASDAQ exchange [of Rockwell’s stock] on October 1, 2014.” (Id. at 10, ECF # 15-10 at 11, Pg. ID 441.) The Option Awards were set “to vest in three equal, annual installments beginning in October 2015.” (Id.)

Chioini completed his negotiations with Baxter on October 1 and 2, and the two companies issued a joint press release announcing the transaction on October 3. (See Compl. at ¶ 29, Pg. ID 9.) The press release explained that Baxter would become “the exclusive distributor of Rockwell’s hemodialysis concentrate and ancillary products in the U.S.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Booth Family Trust v. Jeffries
640 F.3d 134 (Sixth Circuit, 2011)
Randy Alman v. Kevin Reed
703 F.3d 887 (Sixth Circuit, 2013)
Suzanne Kolley v. Adult Protective Services
725 F.3d 581 (Sixth Circuit, 2013)
Picard Chemical Inc. Profit Sharing Plan v. Perrigo Co.
951 F. Supp. 679 (W.D. Michigan, 1996)
Genzer v. Cunningham
498 F. Supp. 682 (E.D. Michigan, 1980)
Abella v. Universal Leaf Tobacco Co., Inc.
546 F. Supp. 795 (E.D. Virginia, 1982)
Cuker v. Mikalauskas
692 A.2d 1042 (Supreme Court of Pennsylvania, 1997)
Houle v. Low
556 N.E.2d 51 (Massachusetts Supreme Judicial Court, 1990)
Virginia M. Damon Trust v. North Country Financial Corp.
406 F. Supp. 2d 796 (W.D. Michigan, 2005)
Madvig v. Gaither
461 F. Supp. 2d 398 (W.D. North Carolina, 2006)
Zapata Corp. v. Maldonado
430 A.2d 779 (Supreme Court of Delaware, 1981)
Bender v. Schwartz
917 A.2d 142 (Court of Special Appeals of Maryland, 2007)
Scalisi Ex Rel. McDonough v. Grills
501 F. Supp. 2d 356 (E.D. New York, 2007)
Day v. Stascavage
251 P.3d 1225 (Colorado Court of Appeals, 2010)

Cite This Page — Counsel Stack

Bluebook (online)
219 F. Supp. 3d 608, 2016 U.S. Dist. LEXIS 147240, 2016 WL 6215994, Counsel Stack Legal Research, https://law.counselstack.com/opinion/sherry-v-chioini-mied-2016.